©2022 Stanford Medicine
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
Not Recruiting
Trial ID: NCT00185809
Purpose
The purpose of this study is to examine breast cancers that express the protein (NIS) that
may be found in malignant breast tissues and to evaluate proteins found in blood and their
relationship to NIS, to test whether iodide can be concentrated by breast cells to possibly
treat some breast cancers with radioactive iodine, and to calculate the amount of radioactive
iodine entering breast cancer cells, how long your cancer retains the agent as well as how
much is taken up by other organs, particularly the thyroid gland.
Official Title
Scintigraphic Assessment of I- Transport in Metastatic Breast Cancer and Evaluation of I31I Ablative Therapy: (Part I) Radioiodide Imaging Study
Stanford Investigator(s)
Irene Wapnir, MD
Professor of Surgery (General Surgery)
Eligibility
Inclusion Criteria:- Only women diagnosed with breast cancer
- 18 years of age or older
- From whom informed consent can be obtained
- Patient is able to provide a fluid (e.g. cyst fluid)
- Patient with blood test that shows protein may allow iodide to accumulate in breast
tissue
- Patient who's breast cancer cells accumulated I123 and held on to it for 24 hours
Exclusion Criteria:- Males
- Children
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Marilyn Florero
6507241953